FDA approves taletrectinib for ROS1-positive non-small cell ...
On June 11, 2025, the Food and Drug Administration approved taletrectinib (Ibtrozi, Nuvation Bio Inc.), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non-small ...
Nuvation Bio Inc. - U.S. Food and Drug Administration ...
Jun 11, 2025 · NEW YORK-- (BUSINESS WIRE)-- Nuvation Bio Inc. (NYSE: NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, …
Description: The purpose of this document is to discuss the clinical considerations and general management of taletrectinib for the treatment of ROS1-positive non-small cell lung cancer …
FDA Approves Taletrectinib for ROS1-Positive NSCLC Treatment
Jun 13, 2025 · FDA approval of Taletrectinib for ROS1 positive Non Small Cell Lung Cancer Taletrectinib was approved by the U.S. Food and Drug Administration (FDA) on June 11, …
IBTROZI for the Treatment of Non-small Cell Lung Cancer, US
Dec 9, 2025 · Credit: Nuvation Bio, Inc. IBTROZI ™ (taletrectinib) is a tyrosine kinase inhibitor indicated for the treatment of adults with locally advanced or metastatic non-small cell lung …
FDA Approves Talectrectinib (Ibtrozi) for ROS1-Positive Lung ...
On June 11, 2025, the U.S. Food and Drug Administration (FDA) approved taletrectinib (Ibtrozi), a new targeted therapy for adults with locally advanced or metastatic ROS1-positive non-small …
Taletrectinib Approved for ROS1-Positive Non–Small Cell Lung ...
Jun 13, 2025 · The FDA has granted approval to the kinase inhibitor taletrectinib (Ibtrozi™, Nuvation Bio Inc.) for the treatment of adults with locally advanced or metastatic ROS1 …
FDA Approves Ibtrozi for ROS1-Positive NSCLC
Jun 11, 2025 · The FDA approved taletrectinib (Ibtrozi, Nuvation Bio), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC).
Taletrectinib Increases Already Broad Selection of ROS1 ...
On June 11, 2025, the FDA approved taletrectinib (Ibtrozi) for the treatment of patients with locally advanced or metastatic ROS1 -positive non–small cell lung cancer (NSCLC). 1 In the wake of …
Taletrectinib Recommended in NCCN Guidelines for ROS1 ...
Jul 31, 2025 · Taletrectinib (Ibtrozi; Nuvation Bio) was added to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology for Non-Small Cell Lung …